Results 11 to 20 of about 674 (175)

ChemInform Abstract: Electrochemical Oxidation of Ergolines.

open access: yesChemInform, 1992
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
K. SEIFERT   +2 more
openaire   +2 more sources

Ropinirole, a Non‐Ergoline Dopamine Agonist [PDF]

open access: yesCNS Drug Reviews, 2005
ABSTRACTDopamine agonists have become indispensable in the treatment of Parkinson's disease. In every‐day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market.
Wolfgang H, Jost, Dieter, Angersbach
openaire   +2 more sources

Pleuropulmonary changes induced by ergoline drugs [PDF]

open access: yesEuropean Respiratory Journal, 1996
Classic ergolines, such as bromocriptine, methysergide and ergotamine, can induce chronic pleuropneumonitis. We present the cases of eight patients who developed similar changes whilst on other ergolines. In this retrospective case study spanning 1985-1995, clinical data, radiological material, pulmonary function, bronchoalveolar lavage and ...
P, Pfitzenmeyer   +7 more
openaire   +2 more sources

Two new dopamine agonists that are long acting in vivo but short acting in vitro.

open access: yes, 1980
The effects of two new ergolines, pergolide and CH29-717, on prolactin secretion in vitro and in vivo were compared with those of bromocriptine. Both ergolines had in vitro potencies similar to that of bromocriptine, but had a shorter duration of action.
Grossman, Ashley   +5 more
core   +2 more sources

Stimulant and hallucinogenic novel psychoactive substances; an update [PDF]

open access: yes, 2023
Introduction: The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs’ clinical and pharmacological issues.
Amira Guirguis
core   +3 more sources

Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood

open access: yes, 2011
The structure activity relationship of highly potent special ergolines which selectively block the chemokine receptor CXCR3 is reported. The most potent compounds showed IC50 values below 10 nM in both ligand binding and Ca2+-mobilization assays. However,
Baenteli, Rolf   +6 more
core   +2 more sources

From Ergolines to Indoles: Improved Inhibitors of the Human H3-Receptor for the Treatment of Narcolepsy

open access: yes, 2014
Ergolines were recently identified as a novel class of H3-Receptor (H3R) inverse agonist. While their optimization led to drug candidates with encouraging properties for the treatment of narcolepsy, brain penetration remained low. To overcome this issue,
Zhang, Xuechun   +13 more
core   +1 more source

Electrochemical synthesis of 2-haloergolines

open access: yes, 1987
Regiosclective halogenation (chlorination, bromination, iodination) of several ergolines to the corresponding 2-halo derivatives was performed in moderate to good yields by potential controlled electrolysis at platinum in acetonitrile in the presence of ...
G. FIORI   +3 more
core   +1 more source

Genetics of ergoline alkaloid formation in Penicillium roquefortii [PDF]

open access: yesApplied and Environmental Microbiology, 1985
Auxotrophic, spore color, and alkaloid biosynthetic mutants of Penicillium roquefortii were selected after N-methyl-N'-nitro-N-nitrosoguanidine treatment. Diploids were obtained via protoplast fusion techniques, and the segregants from a diploid were genetically analyzed. The data demonstrated the potential of parasexual recombination in this organism.
S L, Hong, J E, Robbers
openaire   +2 more sources

Determinants of Improved Dyspnea and Exercise Tolerance With Nasal High‐Flow O2 Therapy in Fibrotic Interstitial Lung Disease: A Pilot Physiological Study

open access: yesRespirology, EarlyView.
We tested the respective effect of high‐flow and supplemental O2 from nasal high‐flow O2 therapy (NHFO2) on dyspnea and exercise tolerance in fibrotic interstitial lung disease. Supplemental O2 and NHFO2 (but not high‐flow) provided improvements in these outcomes at “iso‐O2 saturation” due to reduced ventilatory requirements.
Sarah Thivent   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy